These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35510938)

  • 1. Emergence of Dalbavancin, Vancomycin, and Daptomycin Nonsusceptible Staphylococcus aureus in a Patient Treated With Dalbavancin: Case Report and Isolate Characterization.
    Zhang R; Polenakovik H; Barreras Beltran IA; Waalkes A; Salipante SJ; Xu L; Werth BJ
    Clin Infect Dis; 2022 Oct; 75(9):1641-1644. PubMed ID: 35510938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
    Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
    Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
    Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections.
    Sivori F; Cavallo I; Kovacs D; Guembe M; Sperduti I; Truglio M; Pasqua M; Prignano G; Mastrofrancesco A; Toma L; Pimpinelli F; Morrone A; Ensoli F; Di Domenico EG
    Microbiol Spectr; 2022 Apr; 10(2):e0035122. PubMed ID: 35416701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo acquired daptomycin resistance during treatment of methicillin-resistant Staphylococcus aureus endocarditis.
    Dortet L; Anguel N; Fortineau N; Richard C; Nordmann P
    Int J Infect Dis; 2013 Nov; 17(11):e1076-7. PubMed ID: 23578850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.
    McCurdy SP; Jones RN; Mendes RE; Puttagunta S; Dunne MW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5007-9. PubMed ID: 25987636
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 15. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates.
    Rehm SJ; Boucher H; Levine D; Campion M; Eisenstein BI; Vigliani GA; Corey GR; Abrutyn E
    J Antimicrob Chemother; 2008 Dec; 62(6):1413-21. PubMed ID: 18782781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
    Holubar M; Meng L; Alegria W; Deresinski S
    Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Staphylococcus aureus and antibiotic resistance].
    Sancak B
    Mikrobiyol Bul; 2011 Jul; 45(3):565-76. PubMed ID: 21935792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity and resistance development profiling of dalbavancin.
    Goldstein BP; Draghi DC; Sheehan DJ; Hogan P; Sahm DF
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1150-4. PubMed ID: 17220411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target.
    Lepak A; Marchillo K; VanHecker J; Andes D
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7833-6. PubMed ID: 26392492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.